Bacteriophage Therapy Market, By Targeted Bacteria (Escherichia coli, Staphylococcus aureus, Streptococcus, Pseudomonas aeruginosa, Salmonella, and Others), By Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcera

Bacteriophage Therapy Market, By Targeted Bacteria (Escherichia coli, Staphylococcus aureus, Streptococcus, Pseudomonas aeruginosa, Salmonella, and Others), By Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis, and Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)), By Route of Administration (Oral, Topical, and Parenteral) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Bacteriophage therapy has played a significant role in research fields of molecular biology and biotechnology since a long time. Phage-based treatment therapy is expected to emerge as a new treatment for managing persistent bacterial infections. These factors are widening the potential scope for drug discovery. Increasing prevalence of drug-resistant infections is also expected to drive demand for bacteriophage therapy to help in overcoming an infection outbreak. For instance, as per the Centers for Disease Control and Prevention (CDC), in February 2021, around 129 people from 32 U.S. states were infected with the outbreak of strain Salmonella Infantis infection. Moreover, the CDC had conducted an antibiotic resistance testing on Salmonella bacteria isolated from infected patients, which showed that the outbreak strain was resistant to multiple antibiotics.
Increasing research and development of products is expected to propel the market growth. For instance, in September 2021, Armata Pharamceutical Inc. developed a new synthetic phage candidate targeting pathogen Pseudomonas aeruginosa for treatment of serious respiratory infections, with an emphasis on cystic fibrosis patients.
Market Dynamics
Increasing incidences of antibiotic resistance, rising adoption of inorganic growth strategies by key players, and increasing launches and approval of novel products is expected to drive the growth of global bacteriophage therapy market over the forecast period.
For instance, in February 2021, the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application to conduct the first U.S. clinical trial of an intravenously administered bacteriophage-based therapy. The application for the clinical study was submitted by physician-scientists at the University Of California San Diego School Of Medicine. Following the U.S. FDA approval, the company plans to initiate phase I/II clinical trial study to test AB-SA01, an experimental bacteriophage combination for the treatment of participants with ventricular assist devices (VADs) infected by resistant Staphylococcus aureus (S. aureus).
Key features of the study:
This report provides in-depth analysis of the global bacteriophage therapy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bacteriophage therapy market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Armata Pharmaceuticals, Inc., Eliava Biopreparations Ltd., Pherecydes Pharma, Intralytix, Inc., Phagelux, Inc., Nextbiotics, InnoPhage, Ltd, Locus Biosciences, Inc., TechnoPhage, Eligo Bioscience SA, Phagomed Biopharma GmbH., PhagePro, Inc., Adaptive Phage Therapeutics, Enbiotix, Inc., Intodeworld, Inc., BiomX Ltd., Phi Therapeutics, Fixed-phage Ltd., Micreos BV, ContraFect Corporation, and OPTIPHARM Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global bacteriophage therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bacteriophage therapy market.
Detailed Segmentation:
Global Bacteriophage Therapy Market, By Targeted Bacteria:
Escherichia coli
Staphylococcus Aureus
Streptococcus
Pseudomonas aeruginosa
Salmonella
Others
Global Bacteriophage Therapy Market, By Disease Indication:
Urinary Tract Infections
Chronic Otitis
Dental Extraction
Chronic Ulcerative Colitis
Bone Infection
Wound and Skin Infections
Cystic Fibrosis
Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)
Global Bacteriophage Therapy Market, By Route of Administration:
Oral
Topical
Parenteral
Global Bacteriophage Therapy Market, By Region:
North America
By Targeted Bacteria
Escherichia coli
Staphylococcus aureus
Streptococcus
Pseudomonas aeruginosa
Salmonella
Others
By Disease Indication
Urinary Tract Infections
Chronic Otitis
Dental Extraction
Chronic Ulcerative Colitis
Bone Infection
Wound and Skin Infections
Cystic Fibrosis
Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)
Route of Administration
Oral
Topical
Parenteral
By Country
U.S.
Canada
Latin America
By Targeted Bacteria
Escherichia coli
Staphylococcus aureus
Streptococcus
Pseudomonas aeruginosa
Salmonella
Others
By Disease Indication
Urinary Tract Infections
Chronic Otitis
Dental Extraction
Chronic Ulcerative Colitis
Bone Infection
Wound and Skin Infections
Cystic Fibrosis
Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)
Route of Administration
Oral
Topical
Parenteral
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Targeted Bacteria
Escherichia coli
Staphylococcus aureus
Streptococcus
Pseudomonas aeruginosa
Salmonella
Others
By Disease Indication
Urinary Tract Infections
Chronic Otitis
Dental Extraction
Chronic Ulcerative Colitis
Bone Infection
Wound and Skin Infections
Cystic Fibrosis
Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)
Route of Administration
Oral
Topical
Parenteral
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Targeted Bacteria
Escherichia coli
Staphylococcus aureus
Streptococcus
Pseudomonas aeruginosa
Salmonella
Others
By Disease Indication
Urinary Tract Infections
Chronic Otitis
Dental Extraction
Chronic Ulcerative Colitis
Bone Infection
Wound and Skin Infections
Cystic Fibrosis
Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)
Route of Administration
Oral
Topical
Parenteral
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Targeted Bacteria
Escherichia coli
Staphylococcus aureus
Streptococcus
Pseudomonas aeruginosa
Salmonella
Others
By Disease Indication
Urinary Tract Infections
Chronic Otitis
Dental Extraction
Chronic Ulcerative Colitis
Bone Infection
Wound and Skin Infections
Cystic Fibrosis
Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)
Route of Administration
Oral
Topical
Parenteral
By Country
GCC
Israel
Rest of Middle East
Africa
By Targeted Bacteria
Escherichia coli
Staphylococcus aureus
Streptococcus
Pseudomonas aeruginosa
Salmonella
Others
By Disease Indication
Urinary Tract Infections
Chronic Otitis
Dental Extraction
Chronic Ulcerative Colitis
Bone Infection
Wound and Skin Infections
Cystic Fibrosis
Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)
Route of Administration
Oral
Topical
Parenteral
By Country
South Africa
Central Africa
North Africa
Company Profiles
Armata Pharmaceuticals, Inc.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Eliava Biopreparations Ltd.
Pherecydes Pharma
Intralytix, Inc.
Phagelux, Inc.
Nextbiotics
InnoPhage, Ltd
Locus Biosciences, Inc.
TechnoPhage
Eligo Bioscience SA
Phagomed Biopharma GmbH.
PhagePro, Inc.
Adaptive Phage Therapeutics.
Enbiotix, Inc.
Intodeworld, Inc.
BiomX Ltd.
Phi Therapeutics
Fixed-phage Ltd.
Micreos BV
ContraFect Corporation
OPTIPHARM Co., Ltd.
“*” marked represents similar segmentation in other categories in the respective section.